On April 25, 2021, CanSino Biologics Inc. (here referred to as ‘CanSinoBIO’) launched a ceremony for their Covid-19 vaccine phase III production base in Tianjin, where Jianshun Biosciences Co., Ltd. was awarded as the ‘Outstanding Fighting the epidemic Contribution Supplier’.

The recombinant viral vector vaccine for COVID-19 produced in China(Convidecia, Ad5-nCoV) was co-developed by CanSinoBIO and the Institute of Bioengineering of the Academy of Military Medical Sciences, and is the only single-dose vaccine currently approved for marketing in China.  Jianshun Biosciences worked collaboratively with CanSinoBIO during the initial stage of media and process development, and have significantly shorten the product development to commercialization timeline. 

Jianshun Biosciences is the industrial leader in the field of cell culture media development and manufacturing. It has various in-house cell culture technologies to enable clients’ virus vaccine production using cells such as HEK293, Vero, and MDCK in efficient and cost-effective manners.